Chief Impact Officer
David Graham is Chief Impact Officer at NJOY, a role which leads efforts across the company to maximize the positive impact on public health of the company’s products and services through increasing their reach and effectiveness while including oversight of regulatory affairs for the company. He has extensive experience in nicotine and non-nicotine new product development, tobacco control policy, and related regulation in the international healthcare and e-vapor industries spanning ~ 25 years. Beginning with nicotine replacement therapy (NRT)/smoking cessation products in the UK in 1992, followed by International product and category development roles in Sweden, he moved to the USA in 2000 with Pharmacia, subsequently becoming part of Pfizer and then moving to Johnson & Johnson. In 2013, he joined NJOY to lead the regulatory affairs, quality & compliance function for the company and prepare for regulation by FDA and other regulatory agencies in the US and abroad. In addition to multiple interactions with FDA, and other regulatory agencies internationally, David co-led NJOY’s engagement with the National Institute of Drug Abuse (NIDA) on its Small Business Innovation Research (SBIR) award for NJOY to develop an Electronic Nicotine Delivery System (ENDS) for use for clinical research in smoking cessation, leading to the establishment of the first FDA Drug Master File (DMF) for ENDS products. In late 2016, David co-founded and was President of Reveritas Group, a multi-partner consultancy firm of specialists and preferred providers formed to aid ENDS companies navigate all aspects of FDA’s Premarket Tobacco Application (PMTA) process via a total programming approach, and/or provide select outsourced resources as required. Following FDA’s extension of the PMTA compliance deadline, David returned to NJOY in August 2017 in his current role. David is a graduate of Columbia University with a Master’s in Public Policy & Administration.